Labetalol (versus unexposed) updated on 12-17-2024

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13915
R54473		 Bergman, 2018 Congenital heart defects 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 1.00 [0.60;1.60] 30/74   32,437/83,059 32,467 74
ref
S14250
R56013		 Fisher, 2017 Any Congenital Heart Defects early pregnancy case control unexposed, disease free Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 1.87 [1.03;3.39] 32/49   10,593/21,713 10,625 49
ref
Total 2 studies 1.34 [0.72;2.46] 43,092 123
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bergman, 2018Bergman, 2018 1.00[0.60; 1.60]32,4677454%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Fisher, 2017Fisher, 2017 1.87[1.03; 3.39]10,6254946%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 60% 1.34[0.72; 2.46]43,0921230.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 1.34[0.72; 2.46]43,09212360%NABergman, 2018 Fisher, 2017 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.34[0.72; 2.46]43,09212360%NABergman, 2018 Fisher, 2017 2 Tags Adjustment   - Yes  - Yes 1.34[0.72; 2.46]43,09212360%NABergman, 2018 Fisher, 2017 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.34[0.72; 2.46]43,09212360%NABergman, 2018 Fisher, 2017 2 All studiesAll studies 1.34[0.72; 2.46]43,09212360%NABergman, 2018 Fisher, 2017 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.34[0.72; 2.46]43,09212360%NABergman, 2018 Fisher, 2017 20.510.01.0